We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    GPGN
Previous Study | Return to List | Next Study

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04255433
Recruitment Status : Active, not recruiting
First Posted : February 5, 2020
Last Update Posted : May 24, 2023
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Tirzepatide Drug: Dulaglutide Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13299 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Actual Study Start Date : May 29, 2020
Estimated Primary Completion Date : October 17, 2024
Estimated Study Completion Date : October 17, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Tirzepatide
Tirzepatide administered subcutaneously (SC) once a week.
 Drug: Tirzepatide
Administered SC
Other Name: LY3298176
Active Comparator: Dulaglutide
Dulaglutide administered SC once a week.
 Drug: Dulaglutide
Administered SC
Other Name: LY2189265


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3) [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of a component event of MACE-3


Secondary Outcome Measures :
  1. Time to Death from Any Cause [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to Death from Any Cause

  2. Time to CV Death [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to CV Death

  3. Time to First Occurrence of MI [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of MI

  4. Time to First Occurrence of Stroke [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of Stroke

  5. Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina

  6. Cumulative Number of CV Deaths and Total (First and Recurrent) Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits [ Time Frame: End of Study (Approximate Maximum 54 Months) ]
    Cumulative Number of CV Deaths and Total (First and Recurrent) Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits

  7. Percentage of Participants with More than 10% Weight Loss [ Time Frame: 36 Months ]
    Percentage of Participants with More than 10% Weight Loss

  8. Change from Baseline in Body Weight [ Time Frame: Baseline, End of Study (Approximate Maximum 54 Months) ]
    Change from Baseline in Body Weight

  9. Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, End of Study (Approximate Maximum 54 Months) ]
    Change from Baseline in HbA1c

  10. Change from Baseline in Urinary Albumin to Creatinine Ratio [ Time Frame: Baseline, End of Study (Approximate Maximum 54 Months) ]
    Change from Baseline in Urinary Albumin to Creatinine Ratio

  11. Change from Baseline in Blood Lipids [ Time Frame: Baseline, End of Study (Approximate Maximum 54 Months) ]
    Change from Baseline in Blood Lipids (Total Cholesterol, Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, and Triglycerides)

  12. Time to First Occurrence of Revascularization [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of Revascularization

  13. Time to First Occurrence of Hospitalization Due to Unstable Angina [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of Hospitalization Due to Unstable Angina

  14. Time to First Occurrence of New or Worsening Nephropathy [ Time Frame: Randomization up to Study Completion (Approximate Maximum 54 Months) ]
    Time to First Occurrence of New or Worsening Nephropathy

  15. Cumulative Number of Primary Composite Events of CV Death and Total (First and Recurrent) MI and/or Stroke [ Time Frame: End of Study (Approximate Maximum 54 Months) ]
    Cumulative Number of Primary Composite Events of CV Death and Total (First and Recurrent) MI and/or Stroke


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a diagnosis of type 2 diabetes
  • Have confirmed atherosclerotic cardiovascular disease
  • HbA1c ≥7.0% to ≤10.5%
  • Body mass index (BMI) ≥25 kilograms per meter squared (kg/m²)

Exclusion Criteria:

  • Have had a major cardiovascular event within the last 60 days
  • Have type 1 diabetes mellitus
  • Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
  • Are currently planning treatment for diabetic retinopathy and/or macular edema
  • Currently planning a coronary, carotid, or peripheral artery revascularization
  • Have a history of pancreatitis
  • Have a history of ketoacidosis or hyperosmolar state/coma
  • Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04255433


Locations
Show Show 647 study locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT04255433    
Other Study ID Numbers: 17073
I8F-MC-GPGN ( Other Identifier: Eli Lilly and Company )
2019-002735-28 ( EudraCT Number )
First Posted: February 5, 2020    Key Record Dates
Last Update Posted: May 24, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: http://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eli Lilly and Company:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
 Tirzepatide
Incretins
Glucagon-Like Peptide 1
Gastric Inhibitory Polypeptide
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Dulaglutide
 Tirzepatide
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists